Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered also as a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment [22]. This evidence concerns the gene BACE1 and Alzheimer disease.